Plain-English translation of NCT06401603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of three medications—, lisaftoclax, and —to treat advanced forms of blood cancer that have stopped responding to standard treatments. Researchers want to find the safest and most effective dose of these medications when given together. This is an early-stage study, meaning the treatment is still being refined to understand how well it works and what side effects to expect.
Some patients with advanced blood cancers become resistant to the current standard treatments, leaving them with limited options. This study is exploring whether combining these three medications in a new way might help patients whose disease has become harder to treat.
You likely qualify if…
You likely don't qualify if…
You would take the three medications by mouth according to a set schedule. The study starts with a Phase 1 portion where researchers test different doses to find the safest combination, then moves to Phase 2 where more participants receive the recommended dose. You'll have regular clinic visits for blood tests and check-ups to monitor how the medication is working and to watch for side effects. The study lasts several cycles of treatment, with the possibility of receiving a stem cell transplant later if appropriate.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States